Could a gene therapy be developed for “colour blindness?”

Cure for colour vision deficiency

Avalanche Biotechnologies has an exclusive license agreement with the University of Washington (UW) to develop products based on Avalanche’s proprietary Ocular BioFactory™ Platform for the treatment of colour vision deficiency (CVD), commonly known as red-green colour blindness. On the same day, Avalanche also announced that Drs. Jay and Maureen Neitz, faculty in the UW’s Department [Read More…]